Royce & Associates LP Grows Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Royce & Associates LP grew its stake in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 56.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 371,797 shares of the technology company's stock after purchasing an additional 134,381 shares during the quarter. Royce & Associates LP owned approximately 1.85% of Simulations Plus worth $10,369,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Conestoga Capital Advisors LLC boosted its holdings in Simulations Plus by 15.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company's stock worth $62,090,000 after buying an additional 290,414 shares during the last quarter. Tributary Capital Management LLC boosted its stake in shares of Simulations Plus by 21.7% in the fourth quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company's stock worth $11,047,000 after acquiring an additional 70,526 shares during the last quarter. Stephens Inc. AR acquired a new stake in shares of Simulations Plus in the fourth quarter worth approximately $905,000. BNP Paribas Financial Markets increased its position in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company's stock worth $1,279,000 after purchasing an additional 32,002 shares in the last quarter. Finally, State Street Corp raised its stake in Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company's stock valued at $20,503,000 after purchasing an additional 28,953 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. KeyCorp lifted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. William Blair restated an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Simulations Plus presently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares of the company's stock, valued at $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 19.40% of the company's stock.

Simulations Plus Trading Up 3.6 %

Simulations Plus stock traded up $0.88 during midday trading on Friday, hitting $25.56. 418,730 shares of the stock were exchanged, compared to its average volume of 166,175. The stock's 50-day simple moving average is $31.35 and its 200 day simple moving average is $30.98. Simulations Plus, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The stock has a market capitalization of $513.55 million, a price-to-earnings ratio of 63.90 and a beta of 0.89.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.